Pheochromocytoma Market By Treatment Type (Surgery, Targeted Oral Therapy, Radiopharmaceutical Therapy, Alpha-Adrenergic Blockers, Chemotherapy and Other Systemic Therapies), By Disease Stage (Localized and Resectable Disease, Locally Advanced or Unresectable Disease, Metastatic or Recurrent Disease), By End User (Hospitals and Surgical Centers, Specialty Endocrinology and Oncology Clinics, Nuclear Medicine Centers, Diagnostic and Genetic Testing Laboratories), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Pheochromocytoma Market: Earlier Detection Expands the Care Funnel While Advanced-Disease Treatment Moves Beyond Surgery

The Global Pheochromocytoma Market was valued at an estimated USD 0.84 billion in 2025 and is projected to reach USD 1.45 billion by 2032, expanding at a CAGR of 8.1% during 2026–2032, according to Strategic Market Research.

 

The pheochromocytoma refers to the ecosystem of diagnosis, treatment, and long-term management of a rare neuroendocrine tumor of the adrenal glands, is commercially small by patient count but complex in revenue composition. Most tumors arise in the adrenal medulla and produce excess catecholamines, which can cause hypertension, headache, sweating, palpitations, and potentially severe cardiovascular complications. Some tumors are identified before symptoms develop through adrenal imaging or hereditary-risk screening. This shift toward incidental and genetically directed detection is expanding the number of patients entering specialist care even though the underlying disease remains rare.

 

Key FDA-approved treatments for pheochromocytoma include belzutifan (Welireg), iobenguane I-131 (Azedra), and phenoxybenzamine, each used for different stages of care. Belzutifan is given to patients aged 12 and above with advanced, inoperable, or metastatic disease and helps slow tumor growth. It is taken as a daily oral medicine and is the first and only approved non-surgical oral treatment for this condition in the U.S. It was approved on May 14, 2025, by Merck (MSD outside the U.S.), and the dose is 120 mg once daily for adults and for children over 40 kg, while those under 40 kg receive 80 mg once daily.

 

Azedra (iobenguane I-131) was approved in 2018 as the first systemic treatment for advanced disease and works by delivering targeted radiation to destroy tumor cells, but it was discontinued in 2023, limiting access. In clinical studies, about 25% of patients reduced their blood pressure medication by at least half for six months or more, and around 22% had tumor shrinkage or response. Survival ranged from about 36.7 to 48.7 months depending on treatment exposure, but the drug caused significant side effects including low white blood cells, low platelets, fatigue, and anemia, and production stopped in early 2024.

 

In the United States, pheochromocytoma is a rare condition with an estimated 500 to 1,600 new cases diagnosed annually, while global incidence is about 2 to 8 cases per million people per year. Most tumors are surgically curable, so tracking focuses on both incidence and prevalence, with the U.S. estimated to have roughly 680 to 2,700 living patients. The disease accounts for about 0.1% of adult hypertension cases and up to 1.7% in children, while around 5% of incidentally found adrenal masses on CT or MRI are pheochromocytomas. Most diagnoses now come from imaging or hypertension workups rather than symptoms, reflecting improved detection through modern diagnostic practices.

 

The global annual incidence can also be expressed as approximately 0.2 to 0.8 cases per 100,000 people, which is equivalent to the commonly cited range of 2 to 8 cases per million. Approximately 0.1% of people with hypertension are estimated to have pheochromocytoma, making broad hypertension prevalence a poor direct measure of the commercially addressable population but an important part of the diagnostic funnel.

 

A Rare Epidemiology Base with a Rising Diagnosed Population

Pheochromocytoma and paraganglioma are very rare, with most studies estimating about 2–8 cases per million people each year. A long-term review shows rates rising from ~0.2 per 100,000 before 2000 to ~0.6 per 100,000 after 2010, largely due to better imaging and more frequent incidental detection rather than a true rise in disease.

Many tumors are now found during CT/MRI scans or genetic testing before symptoms appear, and about half of patients may be asymptomatic at diagnosis. This has increased early detection, especially of small adrenal tumors in older adults.

Country-level data varies due to differences in healthcare systems and reporting. For example, incidence ranges from 0.18 per 100,000 in Korea to about 0.66 per 100,000 in Alberta, while Denmark reports a prevalence of 64.4 per million. These differences highlight how diagnosis rates depend heavily on imaging access and clinical practice.

Using post-2010 estimates, the U.S. likely sees roughly 2,000–2,200 new cases per year. However, only a small fraction are eligible for drug therapy, since most localized tumors are treated with surgery and systemic drugs like belzutifan are reserved for advanced or metastatic disease.

 

The Broader Market Is Built Around Detection, Surgery, and Lifelong Follow-Up

Localized adrenal pheochromocytoma is primarily a surgical market. Adrenalectomy remains the definitive treatment for resectable tumors, supported by specialized endocrine surgery, anesthesia, perioperative blood-pressure management, imaging, pathology, and inpatient care. These procedures are concentrated in referral hospitals because catecholamine secretion creates perioperative cardiovascular risks that require coordinated specialist management.

Phenoxybenzamine was traditionally administered for approximately 7 to 14 days before surgery as the standard nonselective alpha-blocker. National U.S. data show that phenoxybenzamine is no longer the most frequently used preoperative agent as its cost and limited availability have encouraged greater use of selective alpha-1 blockers such as doxazosin. Among 552 insured U.S. patients undergoing adrenalectomy for pheochromocytoma, phenoxybenzamine use declined from 71.0% in 2008 to 21.2% in 2019, while selective alpha-blocker use increased from 6.5% to 42.4%. Median phenoxybenzamine prescription cost increased from USD 722 to USD 9,616, representing an increase of more than tenfold. The transition toward selective alpha blockers did not compromise hospital length of stay or increase intensive care unit admission.

A National Cancer Database analysis of 276 patients undergoing adrenalectomy for malignant pheochromocytoma found that 50.7% received open surgery and 49.3% received minimally invasive surgery. Open procedures were associated with larger tumors, averaging 8.2 centimetres compared with 4.7 centimetres for minimally invasive procedures. Median hospital stay was six days after open surgery and three days after minimally invasive surgery. Five-year survival was 74.3% and 79.1%, respectively, with the study supporting minimally invasive surgery as a safe option for appropriately selected tumors smaller than six centimetres.

Partial adrenalectomy is mainly used in patients with hereditary disease, bilateral tumors, or higher risk of recurrence. A SEER study of 286 patients showed no difference in survival compared to full adrenalectomy, but it helps preserve adrenal function and can reduce the need for lifelong steroid therapy.

Surgery is increasingly concentrated in high-volume endocrine centers, which achieve lower operative costs and better efficiency. This centralization improves outcomes but limits the number of hospitals performing these procedures, narrowing the commercial base for surgical tools, perioperative drugs, and related hospital services.

Surgery does not end the commercial care pathway. The NCI reports recurrence rates of approximately 6.5% to 16.5%, often occurring five to fifteen years after initial surgery. Lifelong follow-up is recommended because recurrent or metastatic disease can emerge after a prolonged disease-free interval. This creates recurring demand for biochemical monitoring, imaging, specialist consultations, and genetic assessment even when systemic treatment is not required.

Hereditary risk expands this longitudinal market. Underlying hereditary syndromes may be identified in as many as one-quarter of apparently sporadic cases, leading professional guidance to support genetic-risk evaluation. Testing can affect surgical decisions, surveillance intensity, imaging selection, and screening of relatives. The genetic-testing opportunity is therefore connected to lifetime management and family-based case identification rather than a one-time diagnostic transaction.

 

Belzutifan Creates a New Commercial Path for Advanced Disease

The FDA approval of belzutifan was supported by 72 patients enrolled in the pheochromocytoma and paraganglioma cohort of LITESPARK-015. The confirmed objective response rate was 26%, with a median response duration of 20.4 months. Among responders, 53% maintained a response for at least 12 months. Median time to response was 11 months, indicating that clinical benefit may develop gradually rather than immediately.

The study also measured reductions in antihypertensive treatment, an outcome directly relevant to functional tumors. Nineteen of 60 assessable patients, or 32%, achieved at least a 50% reduction in one or more antihypertensive medicines for a minimum of six months. This links tumor control to a measurable reduction in catecholamine-related treatment burden and may support clinical adoption among patients requiring multiple blood-pressure medicines.

The enrolled population reflected substantial prior treatment exposure. Half had previously received chemotherapy, 44% had received radiopharmaceutical therapy, and 25% had received a vascular endothelial growth factor receptor tyrosine kinase inhibitor. The approval therefore addresses a population with limited established treatment options rather than replacing adrenalectomy for localized disease.

Belzutifan is supported by Phase 2 clinical evidence, including LITESPARK-015, targeting the HIF-2α pathway associated with rare tumor development. Its approval on May 14, 2025, established the first oral systemic pathway specifically approved for advanced PPGL in patients aged 12 years and older. The standard adult dose is 120 mg orally once daily. Pediatric patients weighing at least 40 kg receive 120 mg once daily, while those weighing less than 40 kg receive 80 mg once daily.

An oral therapy can expand access beyond the limited centres that administer radioactive iodine, removing the need for inpatient radiation isolation and complex radiopharmaceutical handling. This improves geographic reach and reduces infrastructure requirements, although use will still be concentrated in specialist endocrine oncology centres.

Adoption will depend on safety monitoring, as the label includes risks of anemia, hypoxia, and embryo-fetal toxicity. This requires regular lab and oxygen checks, adding clinical oversight needs. The relatively slow median time to response also means patients must be carefully selected, especially when rapid tumor or symptom control is required.

Across a pooled clinical safety population of 576 patients receiving belzutifan at the solid-tumor dose of 120 mg once daily, anemia occurred in 84.2% of patients, fatigue in 42.7%, nausea in 24.1%, dyspnea in 21.4%, and hypoxia in 16.3%. These pooled percentages reflect broader solid-tumor and VHL-associated tumor exposure rather than the PPGL cohort alone. In the PPGL-specific LITESPARK-015 population, the current U.S. prescribing information reports anemia in 96% of patients, including Grade 3 anemia in 22%, reinforcing the need for hemoglobin monitoring, transfusion planning, and dose management.

 

Radiopharmaceutical Economics Remain Clinically Relevant but Commercially Fragile

Iobenguane I-131 (Azedra) was the first FDA-approved systemic radiopharmaceutical for advanced pheochromocytoma and paraganglioma, approved in 2018 for patients with unresectable or metastatic disease. In its pivotal trial, about 25% of patients achieved a ≥50% reduction in blood pressure medication use, and 22% had a tumor response. Median overall survival ranged from ~36.7 to 48.7 months depending on follow-up analysis.

Despite clinical benefit, Lantheus discontinued Azedra in 2023 due to low demand, high production costs, and complex inpatient radiation requirements, with only limited supply maintained into early 2024. The therapy also carried significant hematologic toxicity, including high rates of lymphopenia (78%), neutropenia (59%), and thrombocytopenia (50%), requiring intensive monitoring and specialist care.

Japan continues to support MIBG therapy through PDR Pharma’s Raiatt, which remains approved for pheochromocytoma and paraganglioma. Local procurement data from Kanazawa University shows rising usage, with orders increasing from 27 vials in 2025 to 96 vials in 2026, reflecting growing institutional reliance rather than broad national expansion. The product is also used in neuroblastoma, helping sustain production through a wider patient base.

 

Regional Access Is Developing Asynchronously

The United States now has an approved oral systemic therapy for advanced PPGL but no commercially available Azedra supply. Japan maintains an approved MIBG-I131 product and an established specialist procurement pathway. The cited European Medicines Agency product information for Welireg covers von Hippel-Lindau-associated tumors and previously treated advanced renal cell carcinoma but does not include a pheochromocytoma or paraganglioma indication.

These differences create distinct regional treatment markets. U.S. commercial activity is positioned to shift toward oral targeted therapy, supported by established specialty-pharmacy and payer processes. Japan retains a stronger role for domestically supplied therapeutic MIBG and institutional procurement. European access may continue to depend on surgery, radionuclide treatment availability, chemotherapy, targeted medicines used under local protocols, and future regulatory expansion.

Research capacity is also concentrated geographically. A bibliometric analysis covering 8,653 pheochromocytoma-related publications from 2001 to 2021 found that the United States generated 32% of global literature, followed by China with 16%, Japan with 10%, and Germany with 8%. This concentration strengthens the role of U.S., Chinese, Japanese, and German specialist centres in guideline development, genetic research, clinical-trial recruitment, and treatment adoption.

Companies entering this field cannot use a uniform global launch strategy. Evidence requirements, nuclear-medicine infrastructure, reimbursement channels, treatment guidelines, referral networks, and approved indications differ substantially by country. Market access planning must begin at the specialist-centre level rather than through broad national promotional coverage.

 

Mapping Global Growth Patterns Across Key Healthcare Regions

North America represented the largest regional market, with estimated revenue of USD 0.34 billion and a 40.5% share in 2025. Revenue is projected to reach USD 0.55 billion by 2032 at a CAGR of 7.1%. The region’s position is supported by specialist endocrine and oncology centres, established genetic-testing and imaging pathways, payer coverage for advanced therapies, and the May 14, 2025, FDA approval of belzutifan as the first oral therapy for advanced PPGL. The discontinuation of Azedra limits radiopharmaceutical choice, but it also increases the commercial importance of oral treatment and long-term specialist monitoring.

Europe accounted for an estimated USD 0.20 billion in 2025 and is projected to reach USD 0.34 billion by 2032, expanding at a CAGR of 7.9%. Regional demand is supported by established endocrine-surgery networks, genetic services, nuclear-medicine infrastructure, and long-term surveillance systems. The EMA authorized Welireg in the European Union in February 2025 for specified von Hippel-Lindau-associated tumors and advanced renal cell carcinoma, but its current European authorization does not include pheochromocytoma or paraganglioma. Consequently, European PPGL revenue remains more dependent on surgery, diagnostics, monitoring, locally available radionuclide treatment, and future regulatory expansion than the U.S. market.

Asia-Pacific is projected to record the fastest regional expansion, increasing from USD 0.21 billion in 2025 to USD 0.41 billion by 2032 at a CAGR of 10.0%. Its global revenue share is consequently expected to rise from 25.0% to approximately 28.3%. Growth is supported by increasing imaging access, expanding molecular and genetic testing, larger specialist referral networks, and Japan’s continuing use of Raiatt MIBG-I131. PMDA records identify PDR Pharma as the authorization holder for Raiatt, while a March 2026 Kanazawa University procurement notice covered 96 vials through a single-tender process because of the absence of competition for technical reasons. These conditions support treatment availability but also demonstrate the region’s dependence on concentrated suppliers and qualified nuclear-medicine centres.

Latin America generated an estimated USD 0.05 billion in 2025 and is projected to reach USD 0.085 billion by 2032, representing a CAGR of 7.9%. Revenue growth is expected to come from wider access to adrenal imaging, expansion of private oncology and endocrine services, increased use of genetic testing, and greater referral of complex cases to major urban hospitals. Market penetration remains limited by delayed diagnosis, uneven reimbursement for rare-disease testing, and restricted access to specialized systemic and radiopharmaceutical treatment outside leading centres.

The Middle East and Africa market was valued at an estimated USD 0.04 billion in 2025 and is projected to reach USD 0.065 billion by 2032 at a CAGR of 7.2%. Revenue is concentrated in tertiary hospitals and private healthcare systems with endocrine surgery, advanced imaging, genetics, and oncology capacity. Expansion will depend on earlier recognition of adrenal incidentalomas, stronger cross-border referral systems, and improved access to molecular diagnostics and rare-disease medicines. Limited specialist availability and fragmented reimbursement will continue to restrict treatment volumes across lower-resource countries.

 

Key Growth Drivers in Diagnosis and Treatment Expansion

The strongest expansion mechanism is increased detection of small and asymptomatic tumors through abdominal imaging. Each additional incidental diagnosis creates demand for endocrine evaluation, biochemical confirmation, imaging, genetic-risk assessment, surgical consultation, and long-term surveillance. The commercial effect is distributed across the care pathway rather than concentrated in advanced-disease drugs.

Genetic evaluation creates a second source of patient identification. Detecting a hereditary mutation can lead to surveillance of relatives, earlier diagnosis, adrenal-sparing surgery, and longer monitoring periods. It also supports referral to specialist centres capable of managing bilateral, recurrent, or multifocal disease.

Belzutifan adds an FDA-approved oral option for patients who previously had no approved oral therapy specific to PPGL. Its use within an established multi-indication franchise improves commercial durability and may reduce dependence on nuclear-medicine capacity. Coverage policies that remain close to the FDA indication could support uptake, although prior authorization and treatment monitoring will limit prescribing to experienced centres.

 

Key Market Constraints

The main limitation of the pheochromocytoma/PPGL market is its very small patient base. Only a few thousand new U.S. cases occur each year, and most are treatable with surgery, leaving a limited group eligible for systemic therapies. This makes commercial success dependent on strong referral networks, payer access, and sustained treatment use in a narrow population.

Diagnosis is also often delayed because symptoms mimic common conditions like hypertension or anxiety, and patients may move across multiple specialties before reaching a specialist center.

Treatment access is further constrained by infrastructure and safety requirements. Radiopharmaceutical options have shown supply and manufacturing challenges, highlighted by the discontinuation of Azedra despite prior FDA approval and clinical use.

Newer systemic therapies like belzutifan add an oral option but still require careful monitoring due to frequent side effects such as anemia (reported in up to 84% of patients) and hypoxia. Its median response time of around 11 months may also limit use in patients needing faster disease control.

 

Competitive and Strategic Outlook

The pheochromocytoma market is shifting from a surgery-only space to a broader care model that includes earlier detection, genetic testing, long-term monitoring, and targeted drug therapies alongside surgery and radiopharmaceuticals.

Merck is the clear leader in advanced PPGL treatment with Welireg, the first FDA-approved oral therapy for this indication. It is taken once daily (120 mg for adults, 80 mg for lower-weight pediatric patients) and offers an outpatient alternative to hospital-based radiopharmaceuticals. Its use is limited by anemia, risk of hypoxia, and a slow median response time of ~11 months. Despite this, Merck benefits from strong oncology infrastructure across renal cell carcinoma and VHL-related tumors, with Welireg contributing to over USD 700 million in annualized sales across indications. This cross-indication scale, along with established payer pathways and specialty pharmacy networks, supports its adoption in ultra-rare oncology markets.

Pfizer does not have a PPGL-specific drug but plays a supportive role through hospital-based care products used in surgery and crisis management of catecholamine-related complications. Its presence is mainly in perioperative stabilization and intensive care settings rather than targeted therapy.

Novartis is a key player in radiopharmaceutical and precision oncology, with oncology revenues above USD 45 billion. Its radioligand therapy expertise and diagnostic integration position it well for future expansion into rare neuroendocrine tumors, including PPGL, especially in MIBG-avid disease.

Exelixis contributes through off-label use of cabozantinib in neuroendocrine tumors. While not approved for PPGL, its VEGFR/MET inhibition profile is relevant to tumor angiogenesis, and its experience in renal cell carcinoma supports physician familiarity in overlapping treatment pathways.

Lantheus is central to the diagnostic side of PPGL care, with over USD 1 billion in annual revenue. Its MIBG-based imaging agents help identify patients eligible for radiopharmaceutical therapy, making it a key enabler of treatment selection in nuclear medicine workflows.

Amneal supports the ecosystem through generic critical-care drugs used in perioperative and emergency management of PPGL patients. Its role is focused on affordability and access to adrenergic blockers and hospital injectables rather than disease-modifying therapy.

In Japan, PDR Pharma maintains a niche position through its MIBG-based therapy Raiatt, supported by domestic production and centralized hospital procurement. Its success depends on stable isotope supply, specialist treatment centres, and integration into national guidelines.

Future therapies will need to compete in a very small and genetically diverse patient pool, where surgery remains dominant. Differentiation will likely depend on faster response times, better safety profiles, effectiveness after existing therapies like belzutifan, and suitability for outpatient use or non-MIBG-avid tumors.

 

Analyst View

The pheochromocytoma market should not be assessed as a conventional oncology drug market. Surgery captures most localized disease, advanced systemic eligibility is narrow, and individual patients may remain under surveillance for many years without receiving drug therapy. The most dependable revenue base is therefore the longitudinal care ecosystem spanning diagnosis, genetics, surgery, imaging, and monitoring.

The 2025 U.S. approval of belzutifan introduces a commercially scalable oral model into advanced PPGL, while the Azedra experience establishes a clear warning for single-indication radiopharmaceutical economics. Japan’s continued Raiatt procurement indicates that targeted MIBG therapy can remain viable where domestic manufacturing, specialist infrastructure, guideline support, and centralized purchasing are aligned.

Belzutifan’s approval established the first oral systemic option specifically authorized for advanced PPGL, supported by a 26% objective response rate and a 20.4-month median duration of response in LITESPARK-015. Azedra previously achieved the first systemic approval in the indication, with 25% of evaluable patients meeting the antihypertensive-reduction endpoint and 22% achieving an overall tumor response, but its withdrawal demonstrated that ultra-orphan approval alone does not ensure commercial sustainability.

 

Pheochromocytoma Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.84 Billion
Revenue Forecast in 2032	USD 1.45 Billion
Overall Growth Rate	CAGR of 8.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Disease Stage, By End User, By Geography
By Treatment Type	Surgery, Targeted Oral Therapy, Radiopharmaceutical Therapy, Alpha-Adrenergic Blockers, Chemotherapy and Other Systemic Therapies
By Disease Stage	Localized and Resectable Disease, Locally Advanced or Unresectable Disease, Metastatic or Recurrent Disease
By End User	Hospitals and Surgical Centers, Specialty Endocrinology and Oncology Clinics, Nuclear Medicine Centers, Diagnostic and Genetic Testing Laboratories
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing detection of adrenal tumors through advanced imaging, rising adoption of genetic testing for hereditary risk identification, FDA approval of targeted oral therapies for advanced disease, growing demand for long-term monitoring and specialist care pathways
Customization Option	Available upon request